3rd party tested ghk cu Research Peptide — UNYX PeptidesUNYX Peptides GHK-CU 100 mg | 99%+

Liraglutide (Saxenda), administered as a daily 3.0 mg subcutaneous injection, was the first GLP-1 agonist approved specifically for weight management and produces average weight loss of 5-10% in clinical trials

30 mL vial capacity: A 30 mL vial is a significant volume

Physician-Supervised Peptide Therapy Our clinical approach includes: Full wellness evaluation Personalized treatment recommendations Ongoing follow-up support Secure telehealth care Home delivery available for eligible patients GoalBMI Wellness focuses on physician-supervised wellness care tailored to the patients individual goals. Potential Side Effects & Safety Information Like any wellness or medical treatment, peptide therapy may carry risks and possible side effects depending on the peptide used, dosage, and individual response

The findings of this study allowed the research team of Lau et al to conclude that treatment with cagrilintide in doses ranging from 0.3-4.5 mg resulted in significant dose-dependent weight loss

Thats why it can feel very effective at low doses but also why it has a higher risk of overstimulation and side effects